Pharmacoeconomic Assessment of Olanzapine in the Treatment of Refractory Schizophrenia Based on a Pilot Clinical Study

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.15, Iss.1, 1998-01, pp. : 29-35

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Olanzapine: A Pharmacoeconomic Review of its Use in Schizophrenia

By Foster R.H. Goa K.L.

PharmacoEconomics, Vol. 15, Iss. 6, 1999-06 ,pp. : 611-640

Adis International

Access to resources Recommend Favorite

Olanzapine pamoate for the treatment of schizophrenia

By Naber Dieter

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 627-633

Informa Healthcare

Access to resources Recommend Favorite

Pharmacotherapy for treatment-refractory schizophrenia

By Van Sant Scott P Buckley Peter F

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 3, 2011-02 ,pp. : 411-434

Informa Healthcare

Access to resources Recommend Favorite

Efficacy of Olanzapine and Ziprasidone for the Treatment of Schizophrenia: A Systematic Review

By Matza Louis S. Baker Timothy M. Revicki Dennis A.

CNS Drugs, Vol. 19, Iss. 6, 2005-01 ,pp. : 499-515

Adis International

Access to resources Recommend Favorite

Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

By Alvarez E. Bobes J. Gomez J.-C. Sacristan J.A. Canas F. Carrasco J.L. Gascon J. Gibert J. Gutierrez M. for the EUROPA Study Group

European Neuropsychopharmacology, Vol. 13, Iss. 1, 2003-01 ,pp. : 39-48

Elsevier

Access to resources Recommend Favorite